WO1997025999A1 - Peptides for altering osteoblast adhesion - Google Patents
Peptides for altering osteoblast adhesion Download PDFInfo
- Publication number
- WO1997025999A1 WO1997025999A1 PCT/US1997/000716 US9700716W WO9725999A1 WO 1997025999 A1 WO1997025999 A1 WO 1997025999A1 US 9700716 W US9700716 W US 9700716W WO 9725999 A1 WO9725999 A1 WO 9725999A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- arg
- lys
- gly
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Definitions
- the invention relates to peptides containing a cell adhesion-related amino acid sequence, and to devices and biomaterials for implantation coated with or incorporating peptides containing that sequence.
- the challenge is to produce biomaterials that are engineered to elicit specific, clinically-desirable responses from living cells and tissues in a patient's body.
- the swift deposition of bone stabilizes the prosthesis and minimizes motion-induced damage to surgically traumatized tissue at the implantation site.
- Anchorage-dependent cells (such as osteoblasts) must first adhere to a surface in order to perform subsequent cellular functions (e.g., proliferation, deposition of bone tissue, etc.) .
- the present invention relates to novel, heparin- binding, osteoblast-adhesive amino acid sequences of the formula: aa'-aa 2 -aa 3 -aa 4 wherein: aa 1 represents the residue of an amino acid selected from the group consisting of H-Lys, H-Arg, H-Orn, and 6-aminocaproic acid (Acp) ;
- aa 2 , and aa 4 independently represent the residue of an amino acid selected from the group consisting of lysine (Lys) , arginine (Arg) , and ornithine (Om) ; and
- aa 3 represents the residue of an amino acid selected from the group consisting of alanine (Ala) , glycine (Gly) , valine (Val) , leucine (Leu) , isoleucine (lie) , serine (Ser) , threonine (Thr) , cysteine (Cys) , methionine (Met) , asparagine (Asn) , norleucine (Nle) , norvaline (Nva) , and 2-aminobutyric acid (Abu) .
- This peptide sequence has not been previously shown to exhibit any biological activity.
- the invention relates to compounds of formulae
- Aa 1 represents the residue of an amino acid selected from the group consisting of H-Lys, H-Arg, H-Orn, and 6-aminocaproic acid (Acp) ;
- aa 2 , and aa 4 independently represent the residue of an amino acid selected from the group consisting of lysine (Lys) , arginine (Arg) , and ornithine (Orn) ;
- aa 3 represents the residue of an amino acid selected from the group consisting of alanine (Ala) , glycine (Gly) , valine (Val) , leucine (Leu) , isoleucine (lie) , serine (Ser) , threonine (Thr) , cysteine (Cys) , methionine (Met) , asparagine (Asn) , norleucine (Nle) , norvaline (Nva) , and 2-aminobutyric acid (Abu) ; and n is zero or an integer from 1 to 6.
- the invention also includes pharmaceutically acceptable salts of the foregoing compounds .
- the single-letter code for Lys-Arg- Ser-Arg is KRSR.
- the invention in another aspect, relates to a device for implantation in an animal .
- the device comprises a substrate covalently attached to a peptide that includes the cell adhesion-related sequence and that has a molecular weight less than 4 kDa.
- the substrate may be a ceramic, a metal, a polymer, a polymer-coated or glass-coated metal or a composite.
- a preferred peptide has the formula H- Lys-Arg-Met-Arg- (Gly) 3 -OH; H-Lys-Arg-Ala-Arg- (Gly) 3 - OH; H-Arg-Arg-Ser-Arg- (Gly) 3 -OH; H-Orn-Arg-Ser-Arg- (Gly) 3 -OH; H-Lys-Lys-Ser-Lys- (Gly) 3 -OH; or H-Acp-Arg- Ser-Arg- (Gly) 3 -OH, with H-Lys-Arg-Ser-Arg- (Gly) 3 -OH and [KRSR] 4 -MAP being most preferred.
- the peptide may be attached to the substrate through a spacer chosen from the group consisting of poly(glycine) , poly(alanine) , poly(ethyleneimine) , poly(lysine) , hydroxyethylcellulose, poly(ethylene glycol), , ⁇ - alkylenediamines and ⁇ -aminoalkanoic acids.
- a bone prosthetic device is a particularly preferred embodiment of the device aspect of the invention.
- the invention in another aspect, relates to a method for enhancing the stabilization of an implant.
- the implant is provided with a coating of a peptide of molecular weight less than 4 kDa incorporating the cell adhesion-related sequence.
- the coating of peptide is covalently attached to the implant.
- the preferred peptides are as above.
- the invention relates to a method for promoting the adhesion of osteoblasts to a prosthetic device.
- the method comprises providing a peptide of molecular weight less than 4 kDa incorporating the cell adhesion- related sequence at the surface of the prosthetic device.
- Preferred peptides are as above. The most preferred peptide is H-Lys-Arg-Ser-Arg- (Gly) n -OH.
- the invention in yet another aspect, relates to a method for disrupting cell adhesion.
- the method comprises bringing a cell into contact with a compound containing the cell adhesion-related peptide sequence at a concentration sufficient to inhibit cell adhesion.
- the invention in a closely related aspect, relates to a method for treating a disease associated with cell adhesion.
- the method comprises administering to a mammal suffering from such a disease an amount of a compound containing the cell adhesion-related peptide sequence sufficient to inhibit cell adhesion.
- the invention relates to a method of constructing a bone replacement or bone- reconstructive material .
- the method comprises preparing a biodegradable or inert polymer matrix which incorporates the cell adhesion-related peptide sequence, bringing osteoblasts into contact with the polymer matrix and adding growth factors.
- substrate refers to the material that comprises the implant. This will commonly be a metal, such as titanium, or a polvmer or a composite.
- peptide refers to a molecule of less than 10 kilodaltons (kDa) which is a polyamide of ⁇ -aminoacids.
- a "cell adhesion-related peptide” is a peptide that includes a sequence of the formula
- Aa 1 represents the residue of an amino acid selected from the group consisting of H-Lys, H-Arg, H-Orn. and 6-aminocaproic acid (Acp) ;
- aa 2 , and aa 4 independently represent the residue of an amino acid selected from the group consisting of lysine (Lys) , arginine (Arg) , and ornithine (Orn) ;
- aa 3 represents the residue of an amino acid selected from the group consisting of alanine (Ala) , glycine (Gly) , valine (Val) , leucine (Leu) , isoleucine (lie) , serine (Ser) , threonine (Thr) , cysteine (Cys) , methionine (Met) , asparagine (Asn) , norleucine (Nle) , norvaline (Nva) , and 2-aminobutyric acid (Abu) .
- aa 1 may additionally be 6-aminocaproic acid.
- aa 1 is written as Aa 1 and represents H-Lys, H-Arg, H-Orn, and Acp.
- linker refers to a molecule whose chemical reactivity is required to covalently join the substrate to the cell adhesion-related peptide, and which, as distinguished from an activating agent (such as a carbodiimide) , leaves behind a residue that is incorporated in the substrate-peptide structure.
- linkers include aminoalkyi- trialkoxysilanes for linking peptides to glass or titanium (via its surface oxide) and ethylene glycol diglycidyl ether (EGDGE) for linking cell-adhesion- related peptides (or spacers) to substrates having amino or hydroxyl functionalities on their surfaces.
- EGDGE ethylene glycol diglycidyl ether
- spacer refers to a molecule that is covalently attached to, and interposed between, the cell-adhesion-related peptide and the linker or substrate as an alternative to direct attachment of cell adhesion-related peptide to linker or substrate.
- Examples include poly(ethylene imine) , a , ⁇ - alkylenediamines, ⁇ -aminoalkanoic acids and polypeptides not including the cell adhesion-related peptide sequence.
- the spacer may provide the cell adhesion- related peptide sequence with some degree of mobility to allow it better access to the binding site on its target molecule; in this respect the spacer functions as a sort of tether between the cell adhesion-related peptide and the relatively rigid substrate.
- the substrate provides an opportunity to bond to an aldehyde
- poly(ethylene imine) , ethylenediamine or any , ⁇ - alkylenediamine (e.g. hexamethylenediamine) can be employed as a spacer.
- Other spacers may be considered for other chemistries.
- a polypeptide or ⁇ -aminoalkanoic acid spacer can be employed.
- examples include, but are not limited to: poly(glycine) , poly(alanine) , 8-aminooctanoic acid and even random polypeptides.
- any difunctional molecule that can be attached at one of its termini to substrate or linker and at the other to the peptide will function in the invention, as long as the chemistry required for covalent attachment doesn't destroy the binding between the peptide and the target cell.
- Spacers that can be used in the invention include, in addition to those named above, polysilanes, polysiloxanes, hydroxyalkyleellulose, dextran, carboxymethyl- cellulose, poly(carboxymethylethylene imine) , and polyvinyl alcohol .
- spacers between the cell adhesion-related peptide and the substrate can be repeated several times. Subsequent applications of spacers may utilize additional functionalizable groups of the first spacer layer, as for example in hydroxyalkylcelluloses. In that case each successive binding thus involves increasing the number of spacer moieties, resulting in greater amounts of loading on the substrate surface.
- a spacer having multiple side chain amines such as poly(lysine)
- multiple antigenic peptides typically consist of a branched lysine core matrix .
- the branched lysine core provides a scaffolding to support multiple copies of a particular peptide.
- the peptide [aa ] -aa 2 -aa 3 -aa 4 ] 4 -MAP, where four cell adhesion-related peptides are attached to a poly(lysine) MAP is such a molecule and can be described by the following formula:
- the terminology "providing the prosthetic device with a coating of a peptide” includes not only covalent attachment of the peptide to the surface of the device, but also adsorption and mechanical association. The important feature of the method requires that the cell adhesion-related peptide be associated with the surface of the device long enough to initiate adhesion of the osteoblasts and thereby to trigger subsequent cellular events.
- the surface of the titanium device will, by virtue of exposure to the atmosphere, in fact be titanium oxide.
- Titanium oxide and silicon oxide surfaces can be rendered suitable for covalent attachment of peptides by treatment with aminoalkyltrialkoxy- silanes, such as aminopropyltriethoxysilane.
- aminoalkyltrialkylsilanes to derivatize glass is known in the art, and is described in some detail in the examples below. It provides the surface with reactive amino groups, to which peptides or spacers plus peptides can be attached.
- substrates such as polyamides
- the surface in its native form presents amino groups (see US patent 4,693,985, which is incorporated herein by reference) .
- the amino groups can be coupled with the carboxyl function of the cell adhesion-related peptide by procedures well known in the art, such as carbodiimides or EEDQ.
- the amino group can also be coupled with the amino group of peptides via glutaraldehyde or acid chlorides of dibasic acids (e.g. adipoyl chloride) .
- the activated hydroxyls can also be reacted with nucleophiles (amines etc) via methods well known in the art .
- Substrates having free vicinal OH functionalities can be activated by any of the commonly known methods. See Immobilized Affinity Peptide Techniques, Greg T. Hermanson, A. Krisna Mallia, and Paul K. Smith Academic Press, Inc., San Diego CA, (1992) , p. 51- 132, and Affinity Chromatography, A Practical
- Two preferred methods include cyanogen bromide activation and periodate activation.
- Cyanogen bromide reacts with vicinal diols of cellulose to provide imidocarbonate and/or cyanate intermediates. These are highly activated toward nucleophilic attack and can be subsequently reacted with primary amines in the spacer or peptide. The result of the reaction is a peptide or spacer covalently attached to the cellulose through a carbamate.
- the activation reaction is carried out as described by Axen et al . [Nat re 214 , 1302-1304 (1967)] and Cuatrecasas et al . rProc. Nat . Acad. Sci . US 1, 636-643 (1968)] .
- Periodate activation involves the periodate induced oxidative cleavage of vicinal diols to aldehydes, which are similarly reactive toward primary amines.
- a reduction step with sodium cyanoborohydride or similar reducing agent is commonly employed to convert the somewhat hydrolytically labile Schiff base to an alkylamine.
- the C-terminal carboxylic acid residue of an N-protected peptide may be activated with a carbodiimide, such as l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (EDAC) , and coupled with the amine-terminal spacer or linker.
- a carbodiimide such as l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (EDAC)
- EDAC l-ethyl-3- (3- dimethylaminopropyl) carbodiimide
- the coupling may be carried out with EEDQ (2-ethoxy-l-ethoxycarbonyl-l,2-dihydroquinoline) as described in W095/18665.
- EEDQ 2-ethoxy-l-ethoxycarbonyl-l,2-dihydroquinoline
- the unprotected peptide can be reacted with the linker or spacer. One such procedure is
- Aminoalkyltrialkoxysilanes e.g. aminopropyl- trimethoxysilane
- a biomaterial employing cell adhesion-related peptides can be further enhanced by attaching integrin-binding peptides (such as RGD peptides) . This allows one to utilize additional adhesion mechanisms of cells.
- integrin-binding peptides such as RGD peptides
- the cell adhesion-related peptide may be incorporated within a biomaterial, chemically immobilized on a biomaterial surface, or delivered in soluble form to a localized area in order to influence (i.e., to either enhance or to disrupt) the adhesion of cells (such as osteoblasts) or to regulate the presence, conformation, or activity of heparin-containing or heparin-like compounds.
- Bone tissue may be engineered in vitro utilizing a biodegradable or inert polymer containing the cell adhesion-related peptide.
- a matrix or scaffold may be constructed from a polymer mesh of polyethylene terephthalate (PET) or polytetrafluoroethylene (PTFE) , for example.
- PET polyethylene terephthalate
- PTFE polytetrafluoroethylene
- the polymeric material is then hydroxylated according to methods known in the art and the cell adhesion-related peptide is coupled to the polymer using methods already described. Osteoblasts are then cultured with the mesh, and growth factors are added to promote cellular functions such as proliferation and deposition of bone.
- a peptide that interacts with the heparin-like domain of a target glycoprotein include (but are not limited to) the mediation of blood coagulation, hypersensitivity reactions, proliferation of select cell types (such as vascular smooth muscle cells and fibroblasts) , intimal hyperplasia, and angiogenesis.
- Any suitable route of administration may be employed for providing the patient with an effective dosage of the cell adhesion-related peptide in soluble form.
- oral, rectal, parenteral (subcutaneous, intramuscular, intravenous) , transdermal, aerosol and like forms of administration may be employed.
- Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, transdermal delivery systems, and the like. Methods for preparing the dosage forms are well known in the pharmaceutical art.
- compositions of the present invention comprise the cell adhesion-related peptide as the active ingredient, or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier, and optionally, other therapeutic ingredients.
- pharmaceutically acceptable salts or “a pharmaceutically acceptable salt thereof” refer to salts prepared from pharmaceutically acceptable non ⁇ toxic acids or bases.
- Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include acetic, benzenesulfonic (besylate) , benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pa oic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, and the like.
- Suitable pharmaceutically acceptable base addition salts include metal salts (e.g.
- compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
- Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients.
- the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both.
- glass substrates were modified with peptides having the sequence Lysine-Serine-Serine- Arginine-Glycine-Glycine-Glycine, or KSSRGGG (SEQ ID NO:10) , as a control. Osteoblast adhesion on these surfaces was compared to osteoblast adhesion on (1) plain, unmodified glass substrates, (2) glass substrates which were treated with 3- aminopropyltriethoxysilane but were not modified with any peptides, (3) glass substrates modified with the cell-adhesive, integrin-binding peptide Arginine- Glycine-Aspartic Acid-Serine (RGDS) (SEQ ID NO:8) , (4) glass substrates modified with the nonadhesive, control peptide Arginine-Aspartic Acid-Glycine-Serine (RDGS) (SEQ ID NO: 9) and (5) glass substrates modified with a peptide having the sequence Histidine-Histidine-Trypto
- KRSRGGG (SEQ ID NO: 4) 2145** 198
- KSSRGGG (SEQ ID NO: 10) 1808 81
- BMD osteoclasts (bone-resorbing cells) adhere to KRSRGGG-modified surfaces in greater numbers than to other treated or untreated surfaces
- KSSRGGG (SEQ ID NO: 10) 2090 96.8
- KRSRGGG (SEQ ID NO: 4) 2377* 73.6
- Non-bone related cells like fibroblasts and endothelial cells, however, do not adhere in significantly greater numbers to surfaces modified with the KRSR-containing peptide, as shown in Table 4 and 4a.
- KSSRGGG (SEQ ID NO: 10) 1483 92.7
- KRSRGGG (SEQ ID NO: 4) 1600 92.7
- KSSRGGG (SEQ ID NO: 10) 1267 60.4
- KRSRGGG (SEQ ID NO: 4) 1233 115
- KRSR (SEQ ID NO: 1) 1508* 135.2
- KRSR(4) -MAP indicates four residues of KRSR attached to the four primary amines of H 2 Lys (H 2 Lys) LysOH.
- Table 6 demonstrates that spacer length does not significantly affect osteoblast adhesion to KRSR-containing peptides.
- KRSRGGG (SEQ ID NO: 4) 1770 185
- KRSRGGGGGG (SEQ ID NO: 7) 1708 213.5
- Table 7 shows the results of pre-incubation of osteoblasts with either the RGDS-peptide, the KRSR- peptide or the KSSR-peptide prior to adhesion on KRSR peptide-modified substrate.
- Pre-incubation of the osteoblasts with KRSR- containing peptide resulted in a significant decrease in adhesion to KRSR-modified substrate but adhesion was unaffected by pre-incubation with KSSR-containing peptide.
- Pre-incubating the osteoblasts with RGDS peptides did not significantly inhibit adhesion to KRSRGGG-modified substrates.
- KRSRGGG (SEQ ID 100 66.5 85.1 74.6 39.7 NO: 4)
- KSSRGGG (SEQ ID 100 77 88.6 1 30.6 1 23.6 NO: 10)
- KRSRGGG (SEQ 100 81 .63 78.91 66.67 55.5 ID NO: 4)
- KSSRGGG (SEQ 1 00 1 09.52 93.65 1 01 .59 1 07.94 ID NO: 10)
- RGDS (SEQ ID 100 96.2 87.2 89.7 87.2 NO: 8)
- KRSRGGG (SEQ ID 100 83.3 86.36 90.9 77.27 NO: 4)
- KSSRGGG (SEQ ID 100 84.37 101 .56 92.1 8 93.75 NO: 10)
- RGDS (SEQ ID NO: 8) 100 106.27 1 14.08 109.39 104.7
- Table 10 demonstrates that osteoblast adhesion is probably mediated by interaction between the peptide and heparan sulfate.
- the heparinase used degrades heparan sulfate in a very selective manner. Heparinase treatment significantly inhibited adhesion on KRSR peptide-containing substrate as well as on the control substrates (plain glass, aminophase glass, and KSSR peptide-modified substrate) .
- KSSRGGG (SEQ ID NO: 10) 1465 197 540 88
- KRSRGGG (SEQ ID NO: 4) 2145 198 330 35
- Peptides were synthesized on a BioSearch 9500 automated peptide synthesizer using a Merrifield resin and either Fmoc strategy, for the Fmoc- protected RGDS (SEQ ID NO:8) , or tBOC strategy for all other peptides. Hydrofluoric acid cleavage was performed with the "low-high" method [Tarn et al . , J. Am. Chem. Soc. 103, 6442-6455 (1983)] and the peptides were purified using reverse phase chromatography on a Sep-Pak cartridge (Millipore, Bedford, MA) followed by HPLC chromatography (C18 column, gradient 0-60% acetonitrile and 0.1% trifluoroacetic acid) . Purified peptides were examined by amino acid analysis to confirm composition and purity, as well as by automated gas phase sequence analysis to confirm amino acid sequences .
- Peptides were immobilized on substrate surfaces (borosilicate glass, 18 mm round coverslips; Fisher) using silane coupling techniques adapted from published protocols [Weetall Applied Biochem. Biotech. 41, 158-188 (1993) ; Robinson et al . Biochim. Biophys. Acta 242, 659-661 (1971) ; and Baum et al . Biochim. Biophvs. Acta 268, 411-414 (1972)] , the disclosures of which are incorporated herein by reference. Briefly, 3-aminopropyltriethoxysilane (Sigma) was allowed to react with hydroxyl groups on the material surfaces to produce "aminophase" substrates.
- borosilicate glass coverslips (Fisher) were etched for one hour in a 3:1 (v/v) solution of 2 N sulfuric acid and 2 N nitric acid, degreased in acetone and ethanol, and rinsed with distilled water.
- the degreased and acid-etched substrates were placed in glass petri dishes which had been previously cleaned with a 3.5% solution of 30% hydrogen peroxide in 18 M sulfuric acid.
- the substrates were dried at 160°C for at least one hour, rinsed with dry acetone, and immersed in 2% 3-aminopropyltriethoxysilane in dry acetone, supplemented with 2% triethylamine under an argon atmosphere at 400°C for one hour.
- the substrates were rinsed (under an argon atmosphere) once with methylene chloride and twice with dry acetone, and cured under argon at 120°C for three hours.
- the silane-coated substrates possessed exposed amine groups and were, thus, classified as "aminophase" substrates.
- Peptides were covalently bound to immobilized exposed amine groups on the substrate surfaces during a twenty-minute incubation (under argon) with a 25:25:1 (v/v/v) solution of peptide (0.1 mM in dry N,N-dimethylformamide) : l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (2.5 mg/mL in dry N,N-dimethylformamide) : n-ethylmorpholine.
- Unreacted amine groups were passivated by soaking peptide- modified substrates in acetic anhydride for 5 minutes; absorbed peptides were then removed by soaking for 5 minutes in 4 M urea, rinsing in distilled water, and soaking for 5 minutes in 1 M sodium chloride. Peptide-modified substrates were then thoroughly rinsed in distilled water prior to sterilization and use.
- substrates which had been aminated but not peptide-grafted i.e., aminophase substrates
- Substrates which had been etched in a 3:1 (v/v) solution of 2 N sulfuric acid: 2 N nitric acid, degreased in acetone and ethanol, and rinsed copiously with distilled water were used as references. Glass substrates were sterilized via overnight ultraviolet irradiation prior to use in experiments .
- the substrates having the KRSR (SEQ ID N0:1) active sequence and those having the RGDS (SEQ ID NO:8) plus KRSR showed statistically significant osteoblast adhesion.
- the osteoblast adhesion via KRSR appears to complement the enhanced adhesion on surfaces modified with the integrin-binding peptide RGDS.
- Titanium and titanium alloys are often used in dental and orthopedic implants. It is known that within approximately one second of exposure to air, a surface oxide layer (approximately a few nanometers thick) forms on the surface of titanium and titanium alloys. From surface characterization techniques such as X-ray photoe ission spectroscopy, auger electron spectroscopy, and secondary ion mass spectroscopy, it has been determined that the oxide layers on commercial samples are primarily composed of Ti0 2 , with small amounts of the suboxides Ti 2 0 3 and TiO present at the metal/surface oxide interface.
- the stable Ti0 2 oxide layer on titanium and Ti- 6A1-4V samples comprises a surface which can be modified with immobilized peptides via the same silanization techniques used on glass (Si0 2 ) surfaces.
- medical grade Ti-6A1-4V stock ASTM F-136; Osteonics was sectioned into coupons using a low-speed saw equipped with a diamond watering blade.
- the metal coupons were then polished to a 30 micron finish via sanding (using 600 grit paper on a sanding wheel) , polishing to a 15 micron finish and then to a 9 micron finish (using diamond spray on a polishing wheel) , and finally polishing to a 3 micron finish using aluminum oxide (Al 2 0 3 ) mixed with 30% hydrogen peroxide on a polishing wheel) , according to standard techniques. Polished metal coupons were degreased with acetone and ethanol and rinsed copiously with distilled water before peptides were immobilized on the metal surfaces ( via the aforementioned techniques) .
- MOLECULE TYPE peptide
- HYPOTHETICAL no
- ORIGINAL SOURCE synthesis
- SEQUENCE DESCRIPTION SEQ ID NO: 4: Lys Arg Ser Arg Gly Gly Gly
- MOLECULE TYPE peptide
- HYPOTHETICAL no
- ORIGINAL SOURCE synthesis
- SEQUENCE DESCRIPTION SEQ ID NO: 8: Arg Gly Asp Ser
- MOLECULE TYPE peptide
- HYPOTHETICAL no
- ORIGINAL SOURCE synthesis
- SEQUENCE DESCRIPTION SEQ ID NO: 9: Arg Asp Gly Ser
- MOLECULE TYPE peptide
- HYPOTHETICAL no
- ORIGINAL SOURCE synthesis
- SEQUENCE DESCRIPTION SEQ ID NO: 10 Lys Ser Ser Arg Gly Gly Gly
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97904788A EP0877620A4 (en) | 1996-01-16 | 1997-01-15 | Peptides for altering osteoblast adhesion |
JP9526188A JP2000505077A (en) | 1996-01-16 | 1997-01-15 | Peptides for improving osteoblast adhesion |
AU17494/97A AU1749497A (en) | 1996-01-16 | 1997-01-15 | Peptides for altering osteoblast adhesion |
US09/101,649 US6262017B1 (en) | 1996-01-16 | 1997-01-15 | Peptides for altering osteoblast adhesion |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1002696P | 1996-01-16 | 1996-01-16 | |
US60/010,026 | 1996-01-16 | ||
US2918996P | 1996-10-31 | 1996-10-31 | |
US60/029,189 | 1996-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997025999A1 true WO1997025999A1 (en) | 1997-07-24 |
Family
ID=26680652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/000716 WO1997025999A1 (en) | 1996-01-16 | 1997-01-15 | Peptides for altering osteoblast adhesion |
Country Status (6)
Country | Link |
---|---|
US (1) | US6262017B1 (en) |
EP (1) | EP0877620A4 (en) |
JP (1) | JP2000505077A (en) |
AU (1) | AU1749497A (en) |
CA (1) | CA2242911A1 (en) |
WO (1) | WO1997025999A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003044045A2 (en) * | 2001-11-19 | 2003-05-30 | Becton, Dickinson And Company | Peptides promoting cell adherence, growth and secretion |
US7622129B1 (en) | 2002-08-05 | 2009-11-24 | Purdue Research Foundation | Nano-structured polymers for use as implants |
US7833283B2 (en) | 2001-08-16 | 2010-11-16 | Purdue Research Foundation | Material and method for promoting tissue growth |
US8329202B2 (en) | 2004-11-12 | 2012-12-11 | Depuy Products, Inc. | System and method for attaching soft tissue to an implant |
CN111330087A (en) * | 2020-03-31 | 2020-06-26 | 四川大学 | Preparation method of magnesium silicate/polyamino acid composite material capable of being clinically molded |
CN111407927A (en) * | 2020-03-31 | 2020-07-14 | 四川大学 | Clinically moldable magnesium silicate/polyamino acid composite material and application thereof in preparation of bone repair material |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002018423A1 (en) * | 2000-08-31 | 2002-03-07 | University Of Delaware | Bioactive peptide for cell adhesion |
US20030059742A1 (en) * | 2001-09-24 | 2003-03-27 | Webster Thomas J. | Osteointegration device and method |
WO2004096085A2 (en) * | 2003-03-27 | 2004-11-11 | Purdue Research Foundation | Nanofibers as a neural biomaterial |
BRPI0410074B1 (en) | 2003-05-08 | 2020-03-10 | Dsm Ip Assets B.V. | COMPOUNDS, PROCESS FOR THE PREPARATION AND USE OF THE SAME, COMPOSITION, AND, PROCESS FOR INCREASING THE PRODUCTION OF COLLAGEN AND / OR ELASTIN IN HUMAN SKIN AND / OR FOR THE DELAY OR TREATMENT OF SKIN AGING |
US20050063937A1 (en) * | 2003-09-16 | 2005-03-24 | Cheng Li | Multiple-arm peptide compounds, methods of manufacture and use in therapy |
US7163920B2 (en) | 2003-09-30 | 2007-01-16 | Ethicon, Inc. | Peptide with osteogenic activity |
US7807624B2 (en) * | 2006-01-11 | 2010-10-05 | Affinergy, Inc. | Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices |
US20130337028A1 (en) * | 2010-06-25 | 2013-12-19 | Nanovis, Inc. | Biomimetic peptides for bone augmentation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5416402A (en) * | 1977-06-29 | 1979-02-07 | Beecham Group Ltd | Peptide and medical composition containing same |
US5492894A (en) * | 1991-03-21 | 1996-02-20 | The Procter & Gamble Company | Compositions for treating wrinkles comprising a peptide |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2711270A1 (en) | 1976-03-16 | 1977-09-22 | Ici Ltd | ORGANIC MATERIALS WITH SPECIFIC REACTIVE GROUPS |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4279787A (en) | 1979-07-30 | 1981-07-21 | Tetra Consultants Inc. | Method of binding antigens to insoluble polymeric substances |
US4411832A (en) | 1979-11-26 | 1983-10-25 | Pedro Cuatrecasas | Polysaccharide matrices comprising macromolecular spacer arms for use as adsorbents in affinity chromatography techniques |
US4413074A (en) | 1982-01-25 | 1983-11-01 | Brunswick Corporation | Hydrophilic surfaces and process for making the same |
US4973493A (en) | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
US4693985A (en) | 1984-08-21 | 1987-09-15 | Pall Corporation | Methods of concentrating ligands and active membranes used therefor |
US4582875A (en) | 1984-12-07 | 1986-04-15 | Bioprobe International, Inc. | Method of activating hydroxyl groups of a polymeric carrier using 2-fluoro-1-methylpyridinium toluene-4-sulfonate |
EP0215805A1 (en) | 1985-01-18 | 1987-04-01 | MERCK PATENT GmbH | Immunoregulatory peptides |
US5229490A (en) * | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5294551A (en) * | 1987-08-25 | 1994-03-15 | Regents Of The University Of Minnesota | Cell culture substrate coated with polypeptides having fibronectin activity |
US5171271A (en) | 1987-08-25 | 1992-12-15 | Regents Of The University Of Minnesota | Polypeptides with fibronectin activity |
US5354557A (en) | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
US5324819A (en) | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
US5196403A (en) * | 1989-01-27 | 1993-03-23 | Biogen, Inc. | Method of inhibiting platelet activation |
US5198423A (en) | 1989-05-26 | 1993-03-30 | Takara Shuzo Co., Ltd. | Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin |
US5318899A (en) * | 1989-06-16 | 1994-06-07 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5330911A (en) * | 1989-09-28 | 1994-07-19 | Board Of Regents, The University Of Texas System | Surfaces having desirable cell adhesive effects |
US5290763A (en) | 1991-04-22 | 1994-03-01 | Intermedics Orthopedics/Denver, Inc. | Osteoinductive protein mixtures and purification processes |
GB2270076A (en) * | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
CA2144180A1 (en) * | 1992-09-08 | 1994-03-17 | George A. Heavner | Peptide inhibitors of cellular adhesion |
WO1995018665A1 (en) | 1994-01-10 | 1995-07-13 | Hemasure, Inc. | Device and process for removing leukocytes and viral inactivating agents from blood |
US5932545A (en) * | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
-
1997
- 1997-01-15 WO PCT/US1997/000716 patent/WO1997025999A1/en not_active Application Discontinuation
- 1997-01-15 US US09/101,649 patent/US6262017B1/en not_active Expired - Lifetime
- 1997-01-15 AU AU17494/97A patent/AU1749497A/en not_active Abandoned
- 1997-01-15 CA CA002242911A patent/CA2242911A1/en not_active Abandoned
- 1997-01-15 EP EP97904788A patent/EP0877620A4/en not_active Withdrawn
- 1997-01-15 JP JP9526188A patent/JP2000505077A/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5416402A (en) * | 1977-06-29 | 1979-02-07 | Beecham Group Ltd | Peptide and medical composition containing same |
US5492894A (en) * | 1991-03-21 | 1996-02-20 | The Procter & Gamble Company | Compositions for treating wrinkles comprising a peptide |
Non-Patent Citations (2)
Title |
---|
J. ORG. CHEM., 1988, Vol. 53, No. 26, AKIYAMA et al., "N-Hydroxy Amides. Synthesis and Properties of Linear and Cyclic Hexapeptides Containing Three N5-Acetyl-N5-hydroxy-L-ornithine Residues as Models for Ferrichrome", pages 6089-6094. * |
See also references of EP0877620A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833283B2 (en) | 2001-08-16 | 2010-11-16 | Purdue Research Foundation | Material and method for promoting tissue growth |
WO2003044045A2 (en) * | 2001-11-19 | 2003-05-30 | Becton, Dickinson And Company | Peptides promoting cell adherence, growth and secretion |
WO2003044045A3 (en) * | 2001-11-19 | 2004-08-05 | Becton Dickinson Co | Peptides promoting cell adherence, growth and secretion |
US7041506B2 (en) | 2001-11-19 | 2006-05-09 | Becton Dickinson And Company | Peptides promoting cell adherence, growth and secretion |
US7344884B2 (en) | 2001-11-19 | 2008-03-18 | Becton, Dickinson And Company | Peptides promoting cell adherence, growth and secretion |
US7622129B1 (en) | 2002-08-05 | 2009-11-24 | Purdue Research Foundation | Nano-structured polymers for use as implants |
US8906402B2 (en) | 2004-11-12 | 2014-12-09 | Purdue Research Foundation | System and method for attaching soft tissue to an implant |
US8399008B2 (en) | 2004-11-12 | 2013-03-19 | Purdue Research Foundation | System and method for attaching soft tissue to annodized metal implant |
US8329202B2 (en) | 2004-11-12 | 2012-12-11 | Depuy Products, Inc. | System and method for attaching soft tissue to an implant |
US8945601B2 (en) | 2004-11-12 | 2015-02-03 | DePuy Synthes Products, LLC | System and method for attaching soft tissue to an implant |
US9498218B2 (en) | 2004-11-12 | 2016-11-22 | Purdue Research Foundation | System and method for attaching soft tissue to an implant comprising a nanotextured surface |
US9788953B2 (en) | 2004-11-12 | 2017-10-17 | Purdue Research Foundation | System and method of attaching soft tissue to an implant |
US10596001B2 (en) | 2004-11-12 | 2020-03-24 | Purdue Research Foundation | System and method of attaching soft tissue to an implant |
US11141277B2 (en) | 2004-11-12 | 2021-10-12 | Purdue Research Foundation | Metal implant for generating soft tissue and attaching to an implant |
CN111330087A (en) * | 2020-03-31 | 2020-06-26 | 四川大学 | Preparation method of magnesium silicate/polyamino acid composite material capable of being clinically molded |
CN111407927A (en) * | 2020-03-31 | 2020-07-14 | 四川大学 | Clinically moldable magnesium silicate/polyamino acid composite material and application thereof in preparation of bone repair material |
CN111407927B (en) * | 2020-03-31 | 2021-09-24 | 四川大学 | Clinically moldable magnesium silicate/polyamino acid composite material and application thereof in preparation of bone repair material |
CN111330087B (en) * | 2020-03-31 | 2021-09-24 | 四川大学 | Preparation method of magnesium silicate/polyamino acid composite material capable of being clinically molded |
Also Published As
Publication number | Publication date |
---|---|
EP0877620A1 (en) | 1998-11-18 |
US6262017B1 (en) | 2001-07-17 |
JP2000505077A (en) | 2000-04-25 |
CA2242911A1 (en) | 1997-07-24 |
AU1749497A (en) | 1997-08-11 |
EP0877620A4 (en) | 1999-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6262017B1 (en) | Peptides for altering osteoblast adhesion | |
JP4503825B2 (en) | Methods and compositions for preventing adhesion formation in biological tissues | |
EP1673113B1 (en) | Implants with attached silylated therapeutic agents | |
EP0464140B1 (en) | Hydrophobic attachment site for adhesion peptides | |
US5677276A (en) | Immobilization of peptides to hyaluronate | |
US20070254006A1 (en) | Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides | |
KR101822200B1 (en) | Endothelium mimicking nanomatrix | |
US20120201858A1 (en) | Multiple-arm peptide compounds, methods of manufacture and use in therapy | |
US20090149673A1 (en) | Synthetic non-fouling amino acids | |
AU734940B2 (en) | Peptide compositions with growth factor-like activity | |
JP2005058499A (en) | Biological material | |
US20130337028A1 (en) | Biomimetic peptides for bone augmentation | |
JP2003073400A (en) | New peptide having osteogenic activity and osteogenesis stimulator prepared by immobilizing the same | |
JP2008529652A (en) | DNA-based coating for implants | |
CA2286687A1 (en) | Collagen-like polymers with cell binding activity | |
Karadag et al. | Peptide-mediated bone tissue engineering | |
JP7475051B2 (en) | Novel compound and angiogenic agent containing the same | |
WO2020116062A1 (en) | Novel compound and angiogenic agent comprising same | |
JP2012077093A (en) | New peptide having osteogenetic effect and osteogenesis promoter prepared by immobilizing the peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997904788 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2242911 Country of ref document: CA Ref country code: CA Ref document number: 2242911 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09101649 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997904788 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997904788 Country of ref document: EP |